21 results on '"M. ROLDÃO"'
Search Results
2. POS-611 FERRITIN: ONE BIOMARKER, MULTIPLE INTERPRETATIONS
- Author
-
M. ROLDÃO, R. Escoli, H. Gonçalves, F. Sofia, and K. Lopes
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Published
- 2021
- Full Text
- View/download PDF
3. Label-free quantitative mass spectrometry from formalin-fixed paraffin-embedded samples of nasopharyngeal carcinoma: Preliminary results from a non-endemic European cohort of patients
- Author
-
Hugo M. Santos, Miguel Rito, José Cabeçadas, José Luis Capelo-Martínez, E. Netto, M. Roldão, and Luis B. Carvalho
- Subjects
Oncology ,medicine.medical_specialty ,Formalin fixed paraffin embedded ,Proteomic Profiling ,business.industry ,medicine.disease ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Nasopharyngeal carcinoma ,Median follow-up ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,medicine ,Biomarker (medicine) ,Radiology, Nuclear Medicine and imaging ,Biomarker discovery ,business ,Label free - Abstract
AIM: Report our results of biomarker discovery in formalin-fixed paraffin-embedded (FFPE) nasopharyngeal carcinoma (NPC) via proteomic analysis. BACKGROUND: Nasopharyngeal carcinoma (NPC) is a rare cancer in Western countries. Proteomic analysis have already been reported as a useful tool to provide biomarkers. Formalin-fixed paraffin-embedded (FFPE) samples, despite largely underused, can provide invaluable information for biomarker research via proteomic analysis. METHODS: FFPE samples of NPC were submitted to protein extraction followed by FASP-digestion and label-free quantitative mass spectrometry (MS). Patients’ received concurrent chemoradiation with or without adjuvant chemotherapy as per Intergroup 0099 trial. IMRT was delivered following the RTOG0615 specifications. Toxicity was scored using the CTCAE 4.03 tables. Survival was estimated using Kaplan–Meier curves. Log-rank was used to detect differences. KEGG ontology graphics were generated. RESULTS: 28 FFPE samples from NPC patients were used. Patients were: 79% male, 97% Caucasians, 86% WHO type 3, 40% T1, 10% T2, 25% T3, and 25% T4. With a median follow up of 37 months, local control was 83 (T1, 100% T2, T3 and T4), overall survival was 84%, and six patients developed distant metastases. All five patients that died were due to metastatic disease. Tumor samples contained a median of 75% of tumor material. We found Epstein–Barr (EBV) and Herpes simplex (HSV) viruses’ related proteins significantly present in early-stage primary NPC (T1 and T2, p
- Published
- 2020
4. POS-610 PREDICTORS OF ERYTHROPOIETIN HIPORESPONSIVENESS IN PREVALENT PATIENTS ON HEMODIALYSIS: A CROSS-SECTIONAL STUDY
- Author
-
F. Sofia, H. M. Gonçalves, M. Roldão, E. Escoli, and K. Lopes
- Subjects
medicine.medical_specialty ,Nephrology ,business.industry ,Cross-sectional study ,Erythropoietin ,Internal medicine ,medicine.medical_treatment ,medicine ,Hemodialysis ,RC870-923 ,business ,Diseases of the genitourinary system. Urology ,medicine.drug - Published
- 2021
5. Improved long-term results of intensity-modulated radiotherapy for a non-endemic European nasopharyngeal carcinoma cohort: single-center retrospective study
- Author
-
I. Sargento, Teresa Alexandre, M. Ferreira, M. Labareda, A. Mota, Miguel Rito, Rute Pocinho, E. Netto, Susana Esteves, M. Roldão, José Cabeçadas, and Miguel Magalhães
- Subjects
Chemotherapy ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,medicine.disease ,Single Center ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Nasopharyngeal carcinoma ,Median follow-up ,030220 oncology & carcinogenesis ,Cohort ,Biopsy ,Medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,Original Research Article ,business - Abstract
PURPOSE: Report our matured outcomes of European nasopharyngeal carcinoma (NPC) treatment from a non-endemic region in the IMRT era. METHODS: We reviewed 109 consecutive patients with biopsy proven NPC treated between 2009 and 2013. All received IMRT as per RTOG 0615. Toxicity was scored accordingly to CTCAE 4.03. Platinum-based chemotherapy was delivered following the Intergroup 0099. RESULTS: Median age of 53 years; 97% Caucasian; 74% male; 72% WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% N0; 17% N1; 39% N2; 27% N3. Compliance to adjuvant chemotherapy was 88%. With a median follow up of 56 months, the 4-year local control was 90.2% (88.6% for T1; 100% for T2; 85% for T3; and 91.7% for T4), the 4-year distant metastases-free survival was 86% and an overall survival rate was 77%. Local control and survival were better in G3 (p
- Published
- 2020
6. POS-611 FERRITIN: ONE BIOMARKER, MULTIPLE INTERPRETATIONS
- Author
-
K. Lopes, H. M. Gonçalves, M. Roldão, R. Escoli, and F. Sofia
- Subjects
Ferritin ,Oncology ,medicine.medical_specialty ,biology ,Nephrology ,business.industry ,Internal medicine ,biology.protein ,Medicine ,Biomarker (medicine) ,RC870-923 ,business ,Diseases of the genitourinary system. Urology - Published
- 2021
7. EP-1176: Long-term outcomes and toxicity profile of chemoradiation for nasopharyngeal carcinoma
- Author
-
M. Labareda, M. Ferreira, E. Netto, Ricardo Pocinho, Susana Esteves, M. Rito, M. Magalhães, R. Pacheco, J. Cabeçadas, I. Sargento, M. Roldão, A. Mota, and M.T.A. Alexandre
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Hematology ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Long term outcomes ,Radiology, Nuclear Medicine and imaging ,business ,Toxicity profile - Published
- 2018
8. EP-1090: Overall treatment time is not a prognostic factor in chemoradiation for nasopharyngeal carcinoma
- Author
-
T. Alexandre, E. Netto, M. Roldão, J. Cabeçadas, M. Magalhães, A. Mota, M. Ferreira, P. Montalvão, F. Pires, and I. Sargento
- Subjects
Oncology ,medicine.medical_specialty ,Prognostic factor ,business.industry ,Hematology ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Nasopharyngeal carcinoma ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Treatment time ,business - Published
- 2016
9. TREATMENT FAILURE IN HIGH-RISK HEAD AND NECK CANCER TREATED WITH ADJUVANT CHEMORADIATION
- Author
-
M. Ferreira, I. Sargento, M. Marques, João Pedro Oliveira, Eduardo Netto, M. Roldão, S. Torres, and António Moreira
- Subjects
medicine.medical_specialty ,Chemotherapy ,Lung ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,Head and neck cancer ,Hematology ,medicine.disease ,Gastroenterology ,Head and neck squamous-cell carcinoma ,stomatognathic diseases ,medicine.anatomical_structure ,Oncology ,Internal medicine ,medicine ,Stage (cooking) ,Lung cancer ,business ,Pathological - Abstract
Background Adjuvant chemoradiation (adCRT) is the standard of care in resectable high-risk head and neck squamous cell carcinoma (HNSCC). We select patients (pts) for adCRT if they are physically fit and have at least 1 major (extra-capsular nodal spread or positive resection margins) and/or 2 minor (pT4, pN2, perineural or vascular invasion) high risk pathological factors. Loco-regional control and disease-free survival (DFS) are good and the toxicities manageable. The aim of our study was to evaluate the patterns of treatment (tt) failure with this therapy. Methods We reviewed the charts of all pts with resected high-risk HNSCC treated with adCRT, from 2007 to 2011. Pts and disease characteristics, compliance to tt, date and first site of tt failure and disease status at last follow-up (FU) were reviewed. Overall survival (OS) and DFS were estimated using Kaplan-Meier method. Results 221 consecutive pts were included, 93.6% male, median age 52 years. The incidence of stage IVA-B disease (72.8%) and major high risk pathological features such as involved surgical margins (50.6%) and extranodal spread of the disease (52.0%) was high. Compliance to tt was good with 94.5% of pts completing at least 2 cycles of chemotherapy. There were no toxic deaths. With a median FU of 18.8 months, 57 pts (25.8%) experienced disease recurrence. Local or regional recurrence as the first site of tt failure occurred in 25 pts (11.3%) and distant metastasis (mets) occurred in 32 pts (14.5%). The most common site of metastatic disease was the lung (26 pts; 11.7%). Lung recurrence occurred at a median FU of 8 months. Nine pts (4%) recurred with lung mets less than 6 months after the end of adCRT. Five pts were diagnosed of primary lung cancer during FU. At last FU 175 pts (79.2%) were alive; 154 (69.9%) in complete remission. The Kaplan-Meier estimates of 3-year OS and DFS were 68% and 59%, respectively. Conclusions Through adequate selection of pts and supportive measures, high tt compliance and manageable toxicity of adCRT are achieved. The observed early recurrence in a small number of pts, mainly in the lung, might suggest that more detailed pretreatment staging and FU evaluation for early lung disease detection are warranted. Disclosure All authors have declared no conflicts of interest.
10. Eculizumab discontinuation in a patient with atypical hemolytic uremic syndrome after ChAdOx1 nCoV-19 vaccination.
- Author
-
Roldão M, Ferrer F, and Lopes K
- Abstract
Eculizumab has proven to be effective in patients with atypical hemolytic uremic syndrome (aHUS) in clinical trials and in the real world, but the optimal duration of therapy remains unknown. Standard maintenance treatment is often life-long, but the possibility of discontinuation has not yet been systematically tested. We describe a case of aHUS after ChAdOx1 nCoV-19 vaccination in a patient with homozygous CFHR3/CFHR1 gene deletion who discontinued eculizumab maintenance therapy 24 weeks after achieving disease remission. We report the safety of discontinuing eculizumab treatment with the aim of minimizing the risk of adverse reactions, reducing the risk of meningitis, improving quality of life, and reducing the considerable treatment costs., Competing Interests: The authors have no conflict of interest to declare that are relevant to the content of this article., (© Dustri-Verlag Dr. K. Feistle.)
- Published
- 2023
- Full Text
- View/download PDF
11. Vascular access type and mortality in elderly incident hemodialysis patients.
- Author
-
Roldão M, Figueiredo C, Escoli R, Gonçalves H, Sofia F, and Lopes K
- Subjects
- Aged, Humans, Retrospective Studies, Renal Dialysis, Proportional Hazards Models, Kidney Failure, Chronic therapy, Arteriovenous Shunt, Surgical
- Abstract
Introduction: The ideal vascular access type for elderly hemodialysis (HD) patients remains debatable. The aim of this study was to analyze the association between patterns of vascular access use within the first year of HD and mortality in elderly patients., Methods: Single-center retrospective study of 99 incident HD patients aged≥80 years from January 2010 to May 2021. Patients were categorized according to their patterns of vascular access use within the first year of HD: central venous catheter (CVC) only, CVC to arteriovenous fistula (AVF), AVF to CVC, and AVF only. Baseline clinical data were compared among groups. Survival outcomes were analyzed using Kaplan-Meier survival curves and Cox's proportional hazards model., Results: When compared with CVC to AVF, mortality risk was significantly higher among CVC only patients and similar to AVF only group [HR 0.93 (95% CI 0.32-2.51)]. Ischemic heart disease [HR 1.74 (95% CI 1.02-2.96)], lower levels of albumin [HR 2.16 (95% CI 1.28-3.64)] and hemoglobin [HR 4.10(95% CI 1.69-9.92)], and higher levels of c-reactive protein [HR 1.87(95% CI 1.11-3.14)] were also associated with increased mortality risk in our cohort, p<0.05., Conclusion: Our findings suggested that placement of an AVF during the early stages of dialysis was associated with lower mortality compared to persistent CVC use among elderly patients. AVF placement appears to have a positive impact on survival outcomes, even in those who started dialysis with a CVC., (Copyright © 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Acute kidney injury patterns in acute heart failure: The prognostic value of worsening renal function and its timing.
- Author
-
Presume J, Cunha GJL, Rocha BML, Landeiro L, Trevas S, Roldão M, Silva MI, Madeira M, Maltês S, Rodrigues C, Araújo I, and Fonseca C
- Subjects
- Humans, Aged, Aged, 80 and over, Prognosis, Kidney physiology, Kidney Function Tests adverse effects, Retrospective Studies, Stroke Volume, Ventricular Function, Left, Acute Disease, Acute Kidney Injury etiology, Heart Failure
- Abstract
Introduction: Acute decompensated heart failure (ADHF) admissions are frequently complicated by different patterns of serum creatinine (SCr) elevation. We aimed to assess the prognostic impact of worsening renal function (WRF) based on the timing of its occurrence., Methods: This was a retrospective cohort of patients admitted for ADHF. Standard WRF was defined as an increase in SCr of ≥0.3 mg/dl during hospitalization. WRF timing was classified as early (within 48 hours of admission) or late (>48 hours). Acute kidney injury (AKI) at admission was defined as a rise in SCr of ≥0.3 mg/dl from outpatient baseline measurement to first measurement at admission. The primary endpoint was a composite of all-cause mortality or hospitalization for cardiovascular events at one-year follow-up., Results: Overall, 249 patients were included (mean age 77±11 years, 62% with preserved left ventricular ejection fraction). Early WRF occurred in 49 patients (19.7%) and was associated with a higher risk of the primary outcome (HR 2.49; 95% CI 1.66-3.73), whereas late WRF was not (p=0.411). After stratification for the presence of early WRF and/or AKI at admission, only patients with early WRF but no AKI at admission and patients with both AKI at admission and early WRF showed a higher risk of the primary outcome after multivariate Cox regression., Conclusion: Early WRF was associated with a higher risk of the primary outcome. The timing of WRF seems to be an important factor to take into account when considering the prognostic impact of creatinine variations during hospitalization for ADHF., (Copyright © 2023 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. IL-6, malnutrition, and short-term mortality in prevalent hemodialysis patients.
- Author
-
Roldão M, Escoli R, and Santos P
- Published
- 2023
- Full Text
- View/download PDF
14. Predictors of hyporesponsiveness to ESAs in peritoneal dialysis patients: the role of residual renal function.
- Author
-
Roldão M, Gonçalves H, and Ferrer F
- Subjects
- Humans, Kidney physiology, Renal Dialysis, Peritoneal Dialysis, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy
- Published
- 2023
- Full Text
- View/download PDF
15. Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine: A Case Report.
- Author
-
Bouça B, Roldão M, Bogalho P, Cerqueira L, and Silva-Nunes J
- Subjects
- Adult, BNT162 Vaccine, COVID-19 Vaccines adverse effects, Female, Humans, Immunization adverse effects, RNA, Messenger, COVID-19 prevention & control, Diabetes Insipidus, Neurogenic complications, Diabetes Insipidus, Neurogenic etiology, Diabetes Mellitus, Hypophysitis complications
- Abstract
Introduction: Cases of central diabetes insipidus (CDI) have been reported after COVID-19 infection, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications., Case Report: Woman 37 years old, with rheumatoid arthritis under adalimumab (40 mg twice a month) since December 2018. She was in her usual state of health when she has received the second dose of BNT162b2 mRNA COVID-19 vaccine (June 2021). Seven days later, she started reporting intense thirst and polyuria and consulted her family physician., Blood Analysis: creatinine 0.7 mg/dL, glucose 95mg/dL, Na+ 141mEq/L, K+ 3.9 mEq/L, TSH 3.8 mcUI/L (0.38-5.33), FT4 0.9 ng/dL (0.6-1.1), cortisol 215.4 nmol/L (185-624), ACTH 21.9 pg/mL (6- 48), FSH 4.76 UI/L, LH5.62 UI/L, estradiol 323 pmol/L, IGF1 74.8 ng/mL (88-209), PRL 24.7mcg/L (3.3-26.7) osmolality 298.2 mOs/Kg (250- 325); Urine analysis: volume 10200 mL/24h, osmolality 75 mOs/Kg (300-900), density 1.002. On water restriction test: 0' - Serum osmolality 308.8mOsm/Kg vs. urine osmolality 61.0 mOsm/Kg; 60' - urine osmolality 102 mOsm/Kg; urine osmolality 1 h after desmopressine was 511mOsm/kg. MRI revealed no abnormal signs consistent with hypophysitis except for the loss of the posterior pituitary bright spot on T1 weighted imaging. Diagnosis of CDI was assumed, and started therapy with desmopressine. A report of potential adverse effect was addressed to national health authorities., Conclusion: In hypophysitis MRI often shows loss of posterior pituitary bright spot on T1 weighted imaging, pituitary enlargement or stalk thickening but those findings were not present in this patient. To the best of our knowledge, CDI has never been reported following administration of a COVID-19 vaccine., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Bouça, Roldão, Bogalho, Cerqueira and Silva-Nunes.)
- Published
- 2022
- Full Text
- View/download PDF
16. Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis.
- Author
-
Guerreiro R, Henriques C, Trevas S, Gouveia C, Roldão M, Egídio de Sousa I, Faria C, Pimenta G, Araújo I, and Fonseca C
- Abstract
Introduction The marked increase in life expectancy seen in Portugal in the last five decades led to a change in the profile of patients being most commonly admitted in internal medicine wards. In deciding the best care for these patients, prognostication models are needed in order to reduce readmissions, mortality, and adequate care. We aimed to study short and long-term mortality and predictors of all-cause mortality, independently of cause admission, of patients admitted in an internal medicine ward. Methods This two-part, single-center study enrolled patients from October 2013 to October 2014 with a follow-up of 60 months. Results A total of 681 patients were included; the mean age was 75.86 years with 60.4% females. The most frequent comorbidities were anemia, hypertension, and renal impairment. More than half of the population died in the follow-up period (51.5%). Deaths were significantly higher in the first six months after discharge (53% of all deaths) and then decreased abruptly to 11.6% in the second half-year after discharge. Based on the multivariate logistic regression model, with age over 80 years, anemia and neoplasm were independent predictors of short-term (p<0.001, p=0.001, p<0.001, respectively) and long-term (p<0.001 for the three conditions) mortality. Heart failure (p=0.018) and diabetes (p=0.025) were also predictors of long-term mortality. Conclusion High mortality, mainly in the first six months after discharge, elicits strategies targeting transition of care and close follow-up in the first months, which can be the key to improving outcomes. Identification of patients at higher risk may help design realistic models aiming to improve care for this frail population and decrease morbimortality., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2022, Guerreiro et al.)
- Published
- 2022
- Full Text
- View/download PDF
17. Co-Processed Olive Oils with Thymus mastichina L.-New Product Optimization.
- Author
-
Peres F, Roldão M, Mourato M, Martins LL, and Ferreira-Dias S
- Abstract
Olive co-processing consists of the addition of ingredients either in the mill or in the malaxator. This technique allows selecting the type of olives, the ingredients with the greatest flavoring and bioactive potential, and the technological extraction conditions. A new product-a gourmet flavored oil-was developed by co-processing olives with Thymus mastichina L. The trials were performed using overripe fruits with low aroma potential (cv. 'Galega Vulgar'; ripening index 6.4). Experimental conditions were dictated by a central composite rotatable design (CCRD) as a function of thyme (0.4-4.6%, w/w ) and water (8.3-19.7%, w/w ) contents used in malaxation. A flavored oil was also obtained by adding 2.5% thyme during milling, followed by 14% water addition in the malaxator (central point conditions of CCRD). The chemical characterization of the raw materials, as well as the analysis of the flavored and unflavored oils, were performed (chemical quality criteria, sensory analysis, major fatty acid composition, and phenolic compounds). Considering chemical quality criteria, the flavored oils have the characteristics of "Virgin Olive Oil" (VOO), but they cannot have this classification due to legislation issues. Flavored oils obtained under optimized co-processing conditions (thyme concentrations > 3.5-4.0% and water contents varying from 14 to 18%) presented higher phenolic contents and biologic value than the non-flavored VOO. In flavored oils, thyme flavor was detected with high intensity, while the defect of "wet wood", perceived in VOO, was not detected. The flavored oil, obtained by T. mastichina addition in the mill, showed higher oxidative stability (19.03 h) than the VOO and the co-processed oil with thyme addition in the malaxator (14.07 h), even after six-month storage in the dark (16.6 vs. 10.3 h).
- Published
- 2021
- Full Text
- View/download PDF
18. Palliative Care in Heart Failure: Challenging Prognostication.
- Author
-
Egídio de Sousa I, Pedroso A, Chambino B, Roldão M, Pinto F, Guerreiro R, Araújo I, Henriques C, and Fonseca C
- Abstract
Heart failure (HF) is a chronic progressive disease with high morbimortality and poor quality of life (QoL). Palliative care significantly improves clinical outcomes but few patients receive it, in part due to challenging decisions about prognosis. This retrospective study, included all patients consecutively discharged from an Acute Heart Failure Unit over a period of one year, aiming to assess the accuracy of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score in predicting mortality. Additionally, predictors of death at one and three years were explored using a multivariate regression model. The MAGGIC score was useful in predicting mortality, without significant difference between mortality observed at three-years follow-up compared with a mortality given by the score (p=0.115). Selected variables were statistically compared showing that poor functional status, high New York Heart Association (NYHA) at discharge, psychopharmacs use, and high creatininemia were associated with higher mortality (p<0.05). The multivariate regression model identified three predictors of one-year mortality: psychopharmacs baseline use (OR=4.110; p=0.014), angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) medication at discharge (OR=0.297; p=0.033), and higher admission's creatinine (OR=2.473; p=0.028). For three-year mortality outcome, two variables were strong independent predictors: psychopharmacs (OR=3.330; p=0.022) and medication with ACEI/ARB at discharge (OR=0.285; p=0.018). Models' adjustment was assessed through the receiver operating characteristic (ROC) curve. The best model was the one-year mortality (area under the curve, AUC 81%), corresponding to a good discrimination power. Despite prognostication, when setting goals of care an individualised patient-centred approach is imperative, based on the patient's objectives and needs. Risk factors related to poorer outcomes should be considered, in particular, higher NYHA at discharge which also represents symptom burden. Hospitalisation is an opportunity to optimize global care for heart failure patients including palliative care., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2021, Egídio de Sousa et al.)
- Published
- 2021
- Full Text
- View/download PDF
19. Label-free quantitative mass spectrometry from formalin-fixed paraffin-embedded samples of nasopharyngeal carcinoma: Preliminary results from a non-endemic European cohort of patients.
- Author
-
Netto E, Santos H, Carvalho L, Capelo-Martínez JL, Rito M, Cabeçadas J, and Roldão M
- Abstract
Aim: Report our results of biomarker discovery in formalin-fixed paraffin-embedded (FFPE) nasopharyngeal carcinoma (NPC) via proteomic analysis., Background: Nasopharyngeal carcinoma (NPC) is a rare cancer in Western countries. Proteomic analysis have already been reported as a useful tool to provide biomarkers. Formalin-fixed paraffin-embedded (FFPE) samples, despite largely underused, can provide invaluable information for biomarker research via proteomic analysis., Methods: FFPE samples of NPC were submitted to protein extraction followed by FASP-digestion and label-free quantitative mass spectrometry (MS). Patients' received concurrent chemoradiation with or without adjuvant chemotherapy as per Intergroup 0099 trial. IMRT was delivered following the RTOG0615 specifications. Toxicity was scored using the CTCAE 4.03 tables. Survival was estimated using Kaplan-Meier curves. Log-rank was used to detect differences. KEGG ontology graphics were generated., Results: 28 FFPE samples from NPC patients were used. Patients were: 79% male, 97% Caucasians, 86% WHO type 3, 40% T1, 10% T2, 25% T3, and 25% T4. With a median follow up of 37 months, local control was 83 (T1, 100% T2, T3 and T4), overall survival was 84%, and six patients developed distant metastases. All five patients that died were due to metastatic disease. Tumor samples contained a median of 75% of tumor material. We found Epstein-Barr (EBV) and Herpes simplex (HSV) viruses' related proteins significantly present in early-stage primary NPC (T1 and T2, p < 0.01). A pool of 10 proteins was statistically up-regulated in the metastatic group of patients ( p < 0.01). Median survival from this M1 group was <1 year ( p < 0.001)., Conclusions: FFPE samples yielded adequate material for MS analysis. We found EBV and HSV related proteins on early-stage NPC, and proteomic profiling associated with distant metastases, potential candidates of disease biomarkers. Validation is needed., (© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
20. Improved long-term results of intensity-modulated radiotherapy for a non-endemic European nasopharyngeal carcinoma cohort: single-center retrospective study.
- Author
-
Netto E, Ferreira M, Esteves S, Sargento I, Alexandre T, Pocinho R, Mota A, Labareda M, Rito M, Cabeçadas J, Magalhães M, and Roldão M
- Abstract
Purpose: Report our matured outcomes of European nasopharyngeal carcinoma (NPC) treatment from a non-endemic region in the IMRT era., Methods: We reviewed 109 consecutive patients with biopsy proven NPC treated between 2009 and 2013. All received IMRT as per RTOG 0615. Toxicity was scored accordingly to CTCAE 4.03. Platinum-based chemotherapy was delivered following the Intergroup 0099., Results: Median age of 53 years; 97% Caucasian; 74% male; 72% WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% N0; 17% N1; 39% N2; 27% N3. Compliance to adjuvant chemotherapy was 88%. With a median follow up of 56 months, the 4-year local control was 90.2% (88.6% for T1; 100% for T2; 85% for T3; and 91.7% for T4), the 4-year distant metastases-free survival was 86% and an overall survival rate was 77%. Local control and survival were better in G3 (p < 0.001 and p = 0.032, respectively). Xerostomia was the most frequent late toxicity in 55% (n = 60). Hypothyroidism requiring hormonal reposition occurred in 15.5% (n = 17). From the 36 deaths, 20 were due to distant metastases, 3 grade 5 toxicity, 2 from local progression, 5 non-cancer deaths and unknown cause in the remaining 6. On multivariable analysis, age (p = 0.017), local recurrence and distant metastases were associated with death (p < 0.001, both)., Conclusion: Our matured data from the IMRT era showed a major improvement from our 3D cohort series reaching excellent local and regional control, even in T4. Local recurrences, despite few, and distant metastases were correlated with the risk of death., (© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
21. Quality of life and radiotherapy in brain metastasis patients.
- Author
-
Fernandez G, Pocinho R, Travancinha C, Netto E, and Roldão M
- Abstract
Aim: The primary objective of this study was to assess whether there was an improvement in QoL for patients with brain metastases after radiotherapy treatments., Background: Assessment of quality of life (QoL) in brain metastasis patients has become increasingly recognized as an important outcome., Materials and Methods: Patients treated for brain metastasis in our department during 2010 were included in our prospective study. QoL assessments were conducted at baseline, 1 month, and 3 months after completion of whole-brain radiotherapy (WBRT). Wilcoxon test for multiple comparisons was calculated to detect significant differences in global QoL scores., Results: Thirty-nine patients with brain metastases completed the EORTC QLQ-C30/BN-20 questionnaire independently. Median age was 59.9 years (from 37 to 81 years). Our results report differences between the baseline and 3 months in worsening of a global health status (p = 0.034) and cognitive function (p = 0.004), as well as drowsiness (p = 0.001), appetite loss (p = 0.031) and hair loss (p = 0.005). There is a tendency for deterioration of physical function (p = 0.004), communication deficit (p = 0.012), and weakness of legs (p = 0.024), between the baseline and 1 month evaluation. There was no difference in a global cognitive status between different evaluations. Median survival time was 3 months (CI 95% 1.85; 4.15)., Conclusions: Our findings indicate a small deterioration for a global QoL status, and large deterioration for cognitive function after radiation treatments, as well as worsening of brain metastasis related symptom items. Further research is necessary to refine treatment selection for patients with brain metastases, since it may at least contribute to the stabilization of their QoL status.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.